ArticleNPJ Regenerative medicine2026
Cold atmospheric plasma ameliorating skin barrier in chronic kidney disease.
Article in NPJ Regenerative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Chronic kidney disease (CKD)-associated skin complications, including pruritus and xerosis, remain clinically challenging due to poorly understood pathological mechanisms. We utilized human skin tissues, adenine-induced CKD mice, and HaCaT cells to evaluate CAP interventions, including direct irradiation and topical application of CAP-activated hydrogel, on epidermal barrier function. Both CKD patients and mice exhibited significant barrier impairment, characterized by suppressed markers of proliferation (PCNA), differentiation (CK1), cornified envelope (filaggrin, loricrin), and tight junctions (claudin-1). CAP treatment effectively reversed these abnormalities, restoring the keratinocyte proliferation/differentiation balance, promoting terminal differentiation, and reducing transepidermal water loss. Mechanistically, CAP coordinated epidermal homeostasis by activating the β-catenin/YAP1 pathway (promoting regeneration) while concurrently inhibiting PI3K/AKT signaling (facilitating differentiation). CAP effectively restores the molecular machinery required for skin barrier integrity in CKD, alleviating associated dermatopathology. These findings establish a scientific basis for CAP as a non-invasive therapy for CKD-related skin complications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.